These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 38287834)

  • 1. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Zhao S; Guo Y; Yin X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs.
    Zhu B; Wei Y; Zhang M; Yang S; Tong R; Li W; Long E
    Front Pharmacol; 2023; 14():1286449. PubMed ID: 38027027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis.
    Cheng Z; Chu H; Seki E; Lin R; Yang L
    Front Cell Dev Biol; 2024; 12():1431921. PubMed ID: 39071804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD).
    Theys C; Vanderhaeghen T; Van Dijck E; Peleman C; Scheepers A; Ibrahim J; Mateiu L; Timmermans S; Vanden Berghe T; Francque SM; Van Hul W; Libert C; Vanden Berghe W
    Front Mol Med; 2023; 3():1283170. PubMed ID: 39086681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of immune dysregulation in MASLD.
    Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
    Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
    He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D
    World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
    Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.
    Kim SJ; Hyun J
    Mol Cells; 2024 Feb; 47(2):100010. PubMed ID: 38237744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd K; Niziński P; Kasprzak P; Kondracka A; Oniszczuk T; Rusinek A; Oniszczuk A
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated mechanisms of MASLD pathogenesis.
    Li Y; Yang P; Ye J; Xu Q; Wu J; Wang Y
    Lipids Health Dis; 2024 Apr; 23(1):117. PubMed ID: 38649999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.